Stock 4597 SOLASIA PHARMA K.K.
Add to a list
To use this feature you must be a member
Log inSign up

All News Solasia Pharma K.K.

Equities

4597

JP3436500007

Delayed Japan Exchange
Other stock markets
 20:38:22 2024-04-30 EDT 		5-day change 1st Jan Change
26 JPY 0.00% Intraday chart for Solasia Pharma K.K. +4.00% -42.22%
03-04 Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited CI
02-16 Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond CI

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Isofol’s Japanese partner Solasia intensifies its commitment to the clinical development of arfolitixorin
AQ
Solasia Pharma K.K. announced that it has received KRW 504.33 million in funding from Macquarie Group Limited
CI
Solasia Pharma K.K. Announces Finance Via Issuance of Unsecured Straight Bond
CI
Solasia Pharma K.K. announced that it expects to receive KRW 504.33 million in funding from Macquarie Group Limited
CI
Solasia Pharma K.K. Revises Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
CI
Solasia Pharma Narrows Nine-Month Loss as Revenue Gains
MT
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023
CI
Solasia Pharma K.K.(TSE:4597) dropped from S&P Global BMI Index
CI
Solasia Pharma K.K. Provides Consolidated Earnings Guidance for the Fiscal Year Ending December 31, 2023
CI
Solasia Pharma K.K. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Solasia Pharma K.K. Provides Consolidated Earnings Forecasts for the Fiscal Year Ending December 31, 2023
CI
Solasia Pharma Teams Up with WEP Clinical to Supply Anti-Cancer Injection in Europe
MT
Solasia Partners with WEP Clinical to Supply Darvias [Darvias Injection 135Mg] Under a Named Patient Program
CI
Solasia Pharma K.K. Provides Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2023
CI
Solasia Pharma Flags Bigger FY22 Loss Following Unfavorable Results of Cancer Drug Study
MT
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022
CI
An unknown buyer acquired unknown minority stake in Solasia Pharma K.K. from ITOCHU Corporation.
CI
Solasia Pharma K.K. Revises Consolidated Financial Guidance for the Fiscal Year Ending December 31, 2022
CI
Solasia Announces Summary of SP-04 PledOx Development Status
CI
Solasia Launches Anticancer Injection Darvias
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 4597 Stock
  4. News Solasia Pharma K.K.